相对于传统康复，"脑机接口+康复"的效果如何？翔宇医疗表示，目前脑机接口设备在临床应用中案例 较少，但已有积极反馈。针对某一类特定产品或训练部位，脑机接口康复效果优于传统方式，使患者 从"被动康复"向"主动康复"转变。但是针对不同脑机接口范式、患者发病期及损伤程度的具体效果对 比，还缺乏大样本数据的综合性研究。公司正在多中心进行大量临床试验，以统计脑机接口与传统康复 方式的效果对比。 中证报中证网讯(王珞)翔宇医疗在8月5日披露的投资者关系活动记录表中表示，公司脑机接口系列产品 除按照规划快速取得医疗器械注册证外，还需要相关部门出台脑机接口适配费和治疗费等标准，助力脑 机接口技术落地和推广。 对于公司脑机接口产品销售模式和定价策略，翔宇医疗介绍，公司战略重点是尽快实现公司自研的脑机 接口产品与自有康复装备紧密连接，推出成熟、完整的脑机接口整体解决方案，协助院端打造脑机接口 专业治疗中心。首先与顶尖三甲医院、大型综合医院等进行合作，打造区域内的首家脑机接口应用标 杆。然后逐步向普通三甲、优秀二甲医院延伸。适当时机让技术下沉到二级以下医院、社康中心，甚至 部分便携版本进入家庭市场。公司脑机接口解决方案相比依赖外购 ...

格隆汇8月5日｜A股市场脑机接口概念股走强，其中，翔宇医疗涨近12%，创新医疗涨超6%，普利特、 爱朋医疗涨超5%，泰和科技涨超4%，熵基科技涨超3%。 ...

机构表示，脑机接口已历经五十年发展历程，多国为期十年的前期投入已助力脑机接口技术和产业从应 用萌芽期迈入普及期，有望在十年内实现"应用解决方案效果良好，多类解决方案走向成熟的目标"。脑 机接口是事关经济社会发展的战略性领域，其深化发展有利于我国在未来产业科技竞争中抢占制高点。 消息面上，此前有报道称，苹果公司正在与脑机接口公司合作开发"使用大脑信号操纵苹果设备"的技术 标准。周一公布的一段展示视频，首次演示了这项技术的进展。视频显示，作为这场未知试验的参与 者，患有渐冻症的马克.杰克逊在2023年成为首批植入Stentrode的患者。他现在仅凭意念，就能在iPad的 屏幕上选择目标，打开应用程序并撰写信息。 脑机接口概念5日盘中发力上扬，截至发稿，翔宇医疗涨超16%，创新医疗（002173）涨停，爱朋医疗 （300753）涨超8%，倍益康等涨超5%。 ...

脑机接口概念日内震荡走高，翔宇医疗涨超10%，爱朋医疗、创新医疗、倍益康、伟思医疗、三博脑科 等快速跟涨。消息面上，苹果公司正在与脑机接口公司合作开发"使用大脑信号操纵苹果设备"的技术标 准。周一公布的一段展示视频，首次演示了这项技术的进展。演示视频显示，一位渐冻症患者通过脑机 设备成功实现用意念控制iPad操作，并展现应用脑机接口使用"快捷指令"等操作。 ...

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 873690 | 捷众科技 | 1 | 18.62 | 20.45亿 | 74.98 | | 301357 | 北方长龙 | 1 | 12.31 | 123亿 | 287.82 | | 601606 | 长城车工 | 1 | 9.99 | 309亿 | 263.18 | | 000901 | 航天科技 | 4 + | 9.62 | 116亿 | 32.91 | | 836247 | 华密新材 | 1 | 8.72 | 36.16亿 | 44.40 | | 688788 | 科思科技 | 1 | 8.62 | 124亿 | 270.39 | | 300490 | 华自科技 | | 8.62 | 41.70亿 | 32.74 | | 002046 | 国机精工 | 1 | 8.44 | 123亿 | 66.42 | | 688626 | 翔宇医疗 | | 8.36 | 81.28亿 | 73.88 | | 002519 | 银河电子 | 张 | 8.28 | ...

Core Points - Henan Xiangyu Medical Equipment Co., Ltd. has invested 5 million RMB to establish Tianjin Jiechuang Rui Intelligent Technology Co., Ltd., holding 100% of the shares [1] - Tianjin Jiechuang Rui Intelligent Technology Co., Ltd. was founded on July 31, 2025, with a registered capital of 5 million RMB and is located in Tianjin [2] Company Overview - The company operates in the computer, communication, and other electronic equipment manufacturing industry [1] - The legal representative of the company is Li Zhifeng [2] - The company engages in various services including AI application system integration, intelligent robot development and sales, wearable smart device manufacturing, and software development [2] Business Activities - The company is involved in the manufacturing and sales of first and second-class medical devices, as well as providing health consultation services [2] - It also offers technology services, including technical consultation, development, and transfer, as well as information technology consulting [2] - The company has a wide range of activities, including the sale of electronic components, industrial control computers, and general equipment manufacturing [2]

Core Viewpoint - Xiangyu Medical's stock closed at 44.97 yuan, down 2.24%, with a rolling PE ratio of 82.87 times, indicating a high valuation compared to the industry average [1][3]. Company Overview - Xiangyu Medical specializes in the research, production, and sales of rehabilitation medical devices, offering over a thousand products across ten categories, including rehabilitation therapy, training, and assessment [2]. - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology initiatives from different medical and scientific associations [2]. Financial Performance - In the first quarter of 2025, the company reported revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a decline of 41.26% [3]. - The gross profit margin for the company stood at 65.30% [3]. Market Position - Xiangyu Medical's PE ratio of 82.87 times is significantly higher than the industry average of 53.65 times and the median of 37.22 times, placing it at the 102nd position in the industry ranking [1][3]. - As of March 31, 2025, the number of shareholders increased to 5,895, with an average holding value of 352,800 yuan per shareholder [1].

翔宇医疗属于医疗器械板块，公司主营业务为医疗器械的研发、生产和销售。公司产品涵盖多个医疗领 域，包括康复医疗设备等。 截至2025年7月31日收盘，翔宇医疗股价报46.00元，较前一交易日下跌0.55元，跌幅1.18%。当日成交 量为49334手，成交金额达2.27亿元。 来源:金融界 风险提示：股市有风险，投资需谨慎。 从资金流向来看，翔宇医疗7月31日主力资金净流出2320.53万元，占流通市值的0.32%。近期医疗器械 行业受到政策关注，国家医保局新设多项医疗新技术相关价格项目，包括脑机接口等创新技术。 ...

7月30日，医疗器械行业下跌0.38%，今日主力资金流出4.36亿元，成分股41只上涨，56只下跌。 主力资金净流出居前的分别为诺唯赞（1345.21万元）、翔宇医疗（1328.4万元）、山东药玻（1264.96 万元）、ST凯利（1228.57万元）、之江生物（1055.64万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300869康泰医学20.489.647210.99万元7.05%2300760 迈瑞医疗237.962.655584.03万元1.73%3002432九安医疗39.41.184117.95万元9.47%4600587新华医疗 16.813.382981.82万元5.89%5688050爱博医疗77.471.552538.28万元5.85%6300314戴维医疗 14.652.092318.76万元5.67%7300453三鑫医疗8.851.491781.91万元11.83%8300677英科医疗 33.965.51375.80万元1.21%9688029南微医学84.90.981371.50万元3.24%10300529健帆生物 24.370.911339.14万元2.86% 来 ...

Group 1 - The company has completed the non-trading transfer of shares under its 2025 Employee Stock Ownership Plan (ESOP), with 165 employees participating and a total subscription amount of 48.958 million yuan, corresponding to 1.883 million shares [1][2] - The shares were transferred at a price of 26.00 yuan per share, representing 1.1769% of the company's total share capital [2] - The ESOP has a duration of 36 months and a lock-up period of 12 months, starting from the date of the last share transfer to the ESOP account [2]